Compare MLYS & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | CHCO |
|---|---|---|
| Founded | 2019 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2023 | 1995 |
| Metric | MLYS | CHCO |
|---|---|---|
| Price | $20.29 | $141.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $46.33 | ★ $142.40 |
| AVG Volume (30 Days) | ★ 1.4M | 103.6K |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | ★ 37.43 | 13.18 |
| EPS | N/A | ★ 4.55 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.24 |
| Revenue Next Year | N/A | $3.28 |
| P/E Ratio | ★ N/A | $30.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.41 | $113.21 |
| 52 Week High | $47.65 | $148.99 |
| Indicator | MLYS | CHCO |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 50.34 |
| Support Level | N/A | $137.70 |
| Resistance Level | $31.19 | $145.96 |
| Average True Range (ATR) | 1.27 | 2.25 |
| MACD | -0.29 | 0.10 |
| Stochastic Oscillator | 4.06 | 59.93 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.